Halozyme Therapeutics | HALO - Cost Of Sales

Halozyme Therapeutics reported $42.12M in Cost of Sales for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.41M 277K
Agios Pharmaceuticals AGIO:US USD 413K 104K
Alnylam Pharmaceuticals ALNY:US USD 51.27M 10.15M
Amarin AMRN:US USD 23.94M 11.87M
Amgen AMGN:US USD 1.75B 159M
Baxter International BAX:US USD 2.42B 208M
Cara Therapeutics CARA:US USD 2.13M 925K
Eli Lilly And LLY:US USD 1.55B 31M
Esperion Therapeutics ESPR:US USD 4.16M 2.35M
Halozyme Therapeutics HALO:US USD 42.12M 5.2M
Intercept Pharmaceuticals ICPT:US USD 28K 396K
Intra Cellular Therapies ITCI:US USD 6.79M 938K
Intrexon XON:US USD 1.26M 320K
IONIS PHARMACEUT IONS:US USD 3.69M 2.17M
JAZZ PHA JAZZ:US USD 167.36M 33.7M
Mannkind MNKD:US USD 16.12M 1.34M
Nektar Therapeutics NKTR:US USD 6.23M 1.26M
Peregrine Pharmaceuticals PPHM:US USD 28.19M 2.42M
Pfizer PFE:US USD 9.82B 3.73B
Rigel Pharmaceuticals RIGL:US USD 342K 92K
United Therapeutics UTHR:US USD 58.8M 21.6M
Vanda Pharmaceuticals VNDA:US USD 6.24M 82K